Paratek Pharmaceuticals Inc (was acquised by Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings") on 21/09/2023) (PRTK)
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical